{"preliminary_commentary":{"by_channel":{"bluesky_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT03802695","nct_id":"NCT03802695","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03802695. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Recipients with human leukocyte antigen (HLA)-identical related or unrelated or 1-allele mismatched (7/8 alleles) unrelated donor undergoing myeloablative conditioning (MAC); with single- or dual-agent graft-versus-host disease (GVHD) prophylaxis given","label":"Arm A","type":"EXPERIMENTAL"},{"description":"Recipients with haploidentical-related donors undergoing MAC; with single- or dual-agent GVHD prophylaxis given","label":"Arm B","type":"EXPERIMENTAL"},{"description":"Recipients with an HLA-identical related or unrelated donor undergoing MAC; no GVHD prophylaxis given","label":"Arm C","type":"EXPERIMENTAL"},{"description":"Recipients with an HLA-identical related or unrelated donor undergoing non-myeloablative (NMA)/reduced intensity conditioning (RIC); with dual agent GVHD prophylaxis given","label":"Arm D","type":"EXPERIMENTAL"},{"description":"Recipients with 1-allele mismatched (7/8 alleles) unrelated donor undergoing NMA/RIC; with dual-agent GVHD prophylaxis given","label":"Arm E","type":"EXPERIMENTAL"},{"description":"Recipients with haploidentical-related donors undergoing NMA/RIC; with dual-agent GVHD prophylaxis given","label":"Arm F","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-12","type":"ESTIMATED"},"conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes","Mixed Phenotype Acute Leukemia","Acute Lymphoblastic Leukemia"],"enrollment":{"count":300,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"OrcaGraft (Orca-Q)","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2026-09-29","lead_sponsor":"Orca Biosystems, Inc.","official_title":"A Phase 1 Dose Escalation and Expansion Study of Orca-Q, an Engineered Donor Graft Derived From Mobilized Peripheral Blood, in Recipients Undergoing Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Dose Limiting Toxicities through Day +28 (dose escalation)","timeFrame":"28 Days after administration of Orca-Q/OrcaGraft"},{"measure":"Primary Graft failure through Day +28 (dose expansion)","timeFrame":"28 Days after administration of Orca-Q/OrcaGraft"}],"references":[{"citation":"O'Neal J, Mavers M, Jayasinghe RG, DiPersio JF. Traversing the bench to bedside journey for iNKT cell therapies. Front Immunol. 2024 Aug 7;15:1436968. doi: 10.3389/fimmu.2024.1436968. eCollection 2024.","pmid":"39170618","type":"DERIVED"}],"start_date":{"date":"2019-04-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","url":"https://clinicaltrials.gov/study/NCT03802695"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03802695"}